DEFINING TREATMENT REFRACTORINESS IN SCHIZOPHRENIA
DEFINING TREATMENT REFRACTORINESS IN SCHIZOPHRENIA
复制标题
DOI：
10.1093/schbul/16.4.551
复制
发表时间：
1990-01-01
影响因子：
6.6
通讯作者：
MIDHA, KK
中科院分区：
文献类型：
--
作者：
BRENNER, HD;DENCKER, SJ;MIDHA, KK
针对相当少数精神分裂症患者表现出的抗精神病药物治疗无效的性质的研究需要，菲利普·R·A·梅和斯文·乔纳斯·登克发起了一个国际研究小组来讨论这个问题，从1980年在瑞典哥德堡举行的国际神经精神药理学大会开始。研究小组随后于1985年在德意志联邦共和国哈尔开会；1986年在加拿大班夫开会；1988年再次在奥地利特尔夫斯开会。研究小组设定了三个目标：(1)澄清治疗抵抗或难治的概念；(2)提出定义或评级治疗难治程度的标准；(3)探索心理社会和药物治疗在提高治疗难治患者的反应性方面的作用。这篇立场文章代表了研究小组为确定精神分裂症治疗难治性所做努力的精华。
Addressing the need for research on the nature of refractoriness to anti-psychotic drug therapy exhibited by a substantial minority of schizophrenic patients, Philip R.A. May and Sven Jonas Dencker instigated an international study group to discuss this problem, beginning with the International Congress of Neuropsychopharmacology in Goteborg, Sweden, in 1980. The study group subsequently met in Haar, Federal Republic of Germany, in 1985; in Banff, Canada, in 1986; and again in Telfs, Austria, in 1988. The study group set three objectives: (1) to clarify the concept of treatment resistance or refractoriness; (2) to suggest criteria for defining or rating the degree of treatment refractoriness; and (3) to explore the role of psychosocial and drug therapies in increasing the responsiveness of the treatment refractory patient. This position article represents a distillation of the study group's efforts to define treatment refractoriness in schizophrenia.